MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients

Area of Science:

• Neuroimmunology
• Pharmacogenomics
• Biomarker Discovery

Background:

• Anti-interferon beta (IFNβ) antibodies impact treatment efficacy in multiple sclerosis (MS).
• Myxovirus-resistance protein A (MxA) is a key marker of IFNβ biological activity.
• The clinical utility of these markers in routine practice remains debated.

Purpose of the Study:

• To investigate the kinetics of IFNβ bioactivity loss and its correlation with clinical outcomes in MS patients.
• To evaluate MxA mRNA and anti-IFNβ antibodies as predictive markers for treatment response.
• To assess the feasibility of routine monitoring of IFNβ therapy using biological markers.

Main Methods:

• A 3-year longitudinal observational study of 118 treatment-naïve MS patients.
• Quantification of MxA mRNA and interferon receptor mRNA via real-time PCR.
• Detection of anti-IFNβ binding and neutralizing antibodies.
• Clinical assessment of disease activity and disability progression.

Main Results:

• Individual patient responses to IFNβ therapy were highly heterogeneous, with variable timing of bioactivity loss.
• No significant correlation was found between biological markers (MxA, antibodies) and clinical disease activity at the group level.
• Average MxA mRNA levels from 6-24 months predicted a reduced risk of short-term disability progression, independent of relapses.

Conclusions:

• MxA mRNA quantification is a feasible and valuable tool for routine monitoring of IFNβ therapy in MS.
• Sustained MxA induction indicates a more bioactive treatment, correlating with reduced disability severity.
• This approach can guide personalized treatment strategies and optimize therapeutic outcomes in MS.